Description
Composition (Each Tablet Contains):
-
Gabapentin – 300 mg
-
Methylcobalamin (Vitamin B12) – 500 mcg
Category: Neuropathic Pain Management
Form: Tablet
Pack Size: 10×10 Alu-Alu
Product Description:
Dycobal-G is a specialized formulation for the treatment of neuropathic pain, diabetic neuropathy, and other nerve-related disorders. It combines Gabapentin, a GABA analogue that modulates nerve signaling to reduce pain, with Methylcobalamin, a neurologically active form of Vitamin B12 that supports nerve regeneration.
Ideal for patients suffering from nerve tingling, burning sensation, numbness, and shooting pain due to damaged or dysfunctional nerves.
Key Benefits:
-
Provides targeted relief from peripheral neuropathic pain
-
Restores nerve function and promotes myelin sheath repair
-
Reduces nerve inflammation and abnormal nerve firing
-
Improves quality of life in diabetic and post-herpetic neuralgia patients
-
Supports long-term nerve health and pain control
How It Works:
-
Gabapentin binds to voltage-gated calcium channels in the nervous system, reducing the release of excitatory neurotransmitters and calming overactive nerves.
-
Methylcobalamin aids in regeneration of damaged neurons and maintains the integrity of the nerve’s protective myelin sheath, essential for proper signal transmission.
How to Use:
-
Take 1 tablet 1–2 times daily as directed by your physician
-
Swallow whole with water, after meals to reduce gastric discomfort
-
Do not discontinue abruptly without medical advice
Safety Advice:
-
May cause drowsiness or dizziness—avoid driving or operating machinery if affected
-
Do not consume alcohol while taking this medication
-
Use cautiously in elderly patients or those with kidney impairment
-
Keep out of reach of children
Precautions:
-
Inform your doctor if you have a history of epilepsy, renal disease, or depression
-
Not recommended during pregnancy or breastfeeding unless clearly indicated
-
Monitor for mood changes or behavioral symptoms in long-term use
Reviews
There are no reviews yet.